A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of The Beta-3 Agonist KRP-114V in Japanese Subjects With Symptoms of Overactive Bladder

Trial Profile

A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of The Beta-3 Agonist KRP-114V in Japanese Subjects With Symptoms of Overactive Bladder

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Vibegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 06 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 According to the Roivant Sciences media release, the primary endpoint Efficacy (The average number of urgency per 1 day, etc.), Safety Timepoints Bladder diary, Adverse event and adverse drug reaction has been met.
    • 13 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top